NYSE · ENOV
Enovis Corporation
Healthcare · Medical - Devices
$17.77▼ 1.55% ($0.28)at close
After hours$17.775:05 PM ET
Market cap
$1.02B
Valuation
Revenue & margin DCF
Verdict: cheap. Price below all scenarios.
The price needs 1.8% revenue growth a year for 10 years. Our scenarios assume 3.8–6.5%.
That's below its past 4-year pace of 12.0%.
Value per share
Base case
$27.85
Price used $17.77 is 36% below this
USD · TTM ending Jul 3, 2026 · Price Oct 2, 8:00 PM UTC
Revenue each value needs
Revenue today $2.3B. The price needs $2.7B by 2036. Base case: $3.8B. At its recent pace: $7.2B. Bear to Bull: $3.3B to $4.3B.
Revenue today $2.3B. The price needs $2.7B by 2036. Base case: $3.8B. At its recent pace: $7.2B. Bear to Bull: $3.3B to $4.3B.
Revenue in 2036
today $2.3B
−$1.1Bless than the Base case
Value per share · Base case
$27.85
Price $17.77
36% below this
- 10-yr revenue CAGR
- 5.2%
- Ending operating margin
- 7.8%
- Discount rate
- 7.7%
USD · TTM ending Jul 3, 2026 · Price Oct 2, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 41.83% over the last year. Revenue grew 4.89% over the trailing twelve months. Operating margin moved from -34.5% to 4.14%.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price, and the shares now sit around the 31st percentile of their historical P/FCF range. That looks more like a rerating of the multiple than a collapse in the business.
What would invalidate this read
This read changes if operating margin (currently 4.14%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Return analysis
Company profile
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices.
Market multiples
Stock splits
Every 3 shares became 1
Profitability & growth
Analyst consensus
12
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 5, 2026
Q3 FY26 · EPS est $0.76 · Revenue est $557.46M
View
Institutional Sentiment
Enovis Corporation · ENOV
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.